Key facts
- It has raised $62.0M; the latest was Later Stage VC ($44.0M) in Sep 2025.
- Notable investors include Lapam Capital, Proxima Ventures (China), 3E Bioventures (China), BioTrack Capital, Johns Hopkins Technology Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Rapafusyn Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Rapafusyn Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rapafusyn Pharmaceuticals
Developer of non-degrading molecular glues intended to target intracellular and transmembrane proteins considered difficult to drug. The company features cell permeability, selectivity, tunability, and oral delivery, and supports drug discovery and development, enabling biopharmaceutical companies and researchers to advance drug discovery by providing capabilities for effective inhibition of intracellular and transmembrane proteins, which are challenging targets for conventional modalities, thus supporting the development of new therapeutic approaches.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2015
- Employees
- 17
- Website
- rapafusyn.com/
- Ownership
- Privately Held (backing)
Rapafusyn Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rapafusyn Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rapafusyn Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.